Abstract # 170:

Scheduled for Friday, June 19, 2015 05:15 PM-05:30 PM: (Cascade H) Oral Presentation


E. K. Hutchinson
Division of Veterinary Resources, NIH , 9000 Rockville Pike, Building 14A, 121A , Bethesda, MD 20892, USA
     The list of drugs used to treat self-injurious behavior (SIB) in nonhuman primates (NHP) is growing, and both the importance and difficulty of keeping abreast of new information grows with it. Where the perception exists that information about therapies is unclear or ambivalent, practitioners may fall back on using outdated therapies with which they are most familiar even in cases where a better option is available. This presentation will attempt to clarify and summarize the available information about several drugs commonly used in the treatment of SIB. Benzodiazepines are one of the most commonly used classes of drugs owing to their low cost and long history of use, but may exacerbate some cases SIB, and the side-effects of withdrawl often “trap” clinicians into chronic treatment with drugs that might best be used to counteract transient anxiety. Treatments targeting serotonin signaling in the brain, such as tryptophan and selective serotonin reuptake inhibitors, have prolonged times-to-effect but more consistent support in both therapeutic and mechanistic literature. “Newer” treatments targeting other systems, such as guanfacine and extended release naltrexone, are more expensive and have less collective experience using them, but offer viable alternatives when first line treatments fail. The efficacy of these and other pharmaceutical therapies for SIB will be discussed along with features relevant to their practical use, such as dosing, cost, and pharmacokinetics.